Rise in claim denial rates for cancer-related advanced genetic testing
Both the use of next-generation sequencing (NGS) testing for cancer and the rate of claim denials for such testing increased between 2016 and 2021, despite implementation of a recent Medicare national coverage determination that established coverage standards for NGS testing.
The analysis by Georgetown University researchers and colleagues, and funded by a grant from the National Cancer Institute at the National Institutes of Health, appears April 18, 2025, in JAMA Network Open.
The researchers point to several possible ...